newsfilter
← Latest News
GlobeNewswire·

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to